187 related articles for article (PubMed ID: 25017952)
1. Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?
Bonsignori M
Expert Rev Vaccines; 2014 Nov; 13(11):1271-3. PubMed ID: 25017952
[TBL] [Abstract][Full Text] [Related]
2. 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.
Kobie JJ; Alcena DC; Zheng B; Bryk P; Mattiacio JL; Brewer M; Labranche C; Young FM; Dewhurst S; Montefiori DC; Rosenberg AF; Feng C; Jin X; Keefer MC; Sanz I
PLoS One; 2012; 7(4):e35356. PubMed ID: 22530008
[TBL] [Abstract][Full Text] [Related]
3. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.
Bonsignori M; Wiehe K; Grimm SK; Lynch R; Yang G; Kozink DM; Perrin F; Cooper AJ; Hwang KK; Chen X; Liu M; McKee K; Parks RJ; Eudailey J; Wang M; Clowse M; Criscione-Schreiber LG; Moody MA; Ackerman ME; Boyd SD; Gao F; Kelsoe G; Verkoczy L; Tomaras GD; Liao HX; Kepler TB; Montefiori DC; Mascola JR; Haynes BF
J Clin Invest; 2014 Apr; 124(4):1835-43. PubMed ID: 24614107
[TBL] [Abstract][Full Text] [Related]
4. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Kelsoe G; Moody MA; Haynes BF
Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 neutralizing antibodies: understanding nature's pathways.
Mascola JR; Haynes BF
Immunol Rev; 2013 Jul; 254(1):225-44. PubMed ID: 23772623
[TBL] [Abstract][Full Text] [Related]
6. Approaches to the induction of HIV broadly neutralizing antibodies.
Moore PL; Williamson C
Curr Opin HIV AIDS; 2016 Nov; 11(6):569-575. PubMed ID: 27559709
[TBL] [Abstract][Full Text] [Related]
7. Natural infection as a blueprint for rational HIV vaccine design.
van Haaren MM; van den Kerkhof TL; van Gils MJ
Hum Vaccin Immunother; 2017 Jan; 13(1):229-236. PubMed ID: 27649455
[TBL] [Abstract][Full Text] [Related]
8. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
Finney J; Kelsoe G
Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
10. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
Sliepen K; Sanders RW
Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibodies and vaccine design against HIV-1 infection.
Wang Q; Zhang L
Front Med; 2020 Feb; 14(1):30-42. PubMed ID: 31858368
[TBL] [Abstract][Full Text] [Related]
13. 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles.
Alcéna DC; Kobie JJ; Kaminski DA; Rosenberg AF; Mattiacio JL; Brewer M; Dewhurst S; Dykes C; Jin X; Keefer MC; Sanz I
PLoS One; 2013; 8(12):e85098. PubMed ID: 24386452
[TBL] [Abstract][Full Text] [Related]
14. Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
Walker LM; Burton DR
Curr Opin Immunol; 2010 Jun; 22(3):358-66. PubMed ID: 20299194
[TBL] [Abstract][Full Text] [Related]
15. Immunological mechanisms of inducing HIV immunity in infants.
Fouda GG; De Paris K; Levy O; Marchant A; Gray G; Permar S; Marovich M; Singh A
Vaccine; 2020 Jan; 38(3):411-415. PubMed ID: 31761501
[TBL] [Abstract][Full Text] [Related]
16. Host controls of HIV broadly neutralizing antibody development.
Kelsoe G; Haynes BF
Immunol Rev; 2017 Jan; 275(1):79-88. PubMed ID: 28133807
[TBL] [Abstract][Full Text] [Related]
17. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
18. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
[TBL] [Abstract][Full Text] [Related]
19. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.
Verkoczy L; Diaz M
Curr Opin HIV AIDS; 2014 May; 9(3):224-34. PubMed ID: 24714565
[TBL] [Abstract][Full Text] [Related]
20. Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies.
Singh H; Henry KA; Wu SS; Chruscinski A; Utz PJ; Scott JK
AIDS; 2011 Jun; 25(10):1247-57. PubMed ID: 21508803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
